Loading search results
BoneFlo
Analysis of the Intraoperative Use and Handling of the Boneflo Tissue Collector System in Orthopedic and Trauma Surgery
Sponsor study identifier
Secondary identifiers
OTHER · Ärztekammer Niedersachsen (Ethics Committee)
interventional
100
1 country
1
Study Start
July 1, 2024
Actual (reported)Primary Completion
March 1, 2026
Actual (reported)Study Completion
March 1, 2026
Actual (reported)Critical bone defects, non-unions, and delayed bone healing remain major challenges in orthopedic and trauma surgery and often require bone grafting. While a patient's own bone (autograft) is considered the gold standard, its use is limited by donor-site morbidity and limited availability. Synthetic bone substitutes offer an alternative but mainly provide structural support and lack biological activity. This prospective multicenter pilot study evaluates the safety and feasibility of using the Boneflo® Tissue Collector System to biologically activate bone substitutes during surgery. The device collects the patient's own tissue, blood, and biologically active factors directly from the surgical site using a vacuum-assisted suction system with an integrated filter. This material is then used intraoperatively to coat and bioactivate bone substitute materials. In healing attempts, 50 patients with critical bone defects, non-unions, or impaired bone healing were treated across four centers. Various bone substitutes, including synthetic calcium phosphate materials, collagen-based scaffolds, and allografts, were used. The primary aim of the study was to evaluate device safety, intraoperative usability, handling, and applicability for coating and activating bone substitutes. The device was evaluated by orthopedic surgeons and other medical professionals, including nurses, physician assistants, and technical assistants. Furthermore, these data were supplemented with clinical outcome data from healing attempts, including wound healing and radiographic bone regeneration, assessed over a minimum six-month follow-up period.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 1, 2026
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 1, 2024
Actual (reported)March 1, 2026
Actual (reported)March 1, 2026
Actual (reported)April 17, 2026
Actual (reported)May 1, 2026
Actual (reported)Incidence of device-related adverse events (% of participants)
Assessment of safety of the surgical suction device used for intraoperative bioactivation of bone substitutes, measured by the number and proportion of participants experiencing device-related adverse events, as recorded in clinical evaluation and adverse event reporting.
Up to 30 days postoperatively
Surgeon-reported usability score (Likert scale)
Immediately after the procedure
Rate of successful intraoperative bioactivation procedures
Intraoperatively (during the index surgical procedure)
Synthetic bone substitutes were intraoperatively activated using autologous tissue in patients with critical bone defects, non-unions, and delayed bone healing. During surgery, autologous tissue, blood, and biologically active components were collected from the surgical site under vacuum conditions using an integrated filter system. The collected material was used to coat and biologically activate bone substitutes, including calcium phosphate ceramics, collagen-based scaffolds, and allografts. The primary focus was on safety, intraoperative usability, handling, and applicability of the device for bone substitute bioactivation. These data were combined with clinical outcomes in healing attempts, including wound healing and radiographic bone regeneration over a six-month follow-up period.
During surgery, autologous tissue, blood, and biologically active components are collected from the surgical site under vacuum conditions with an integrated filter system using the BoneFlo tissue collector. The collected autologous material is used to coat and biologically enhance bone substitutes. Bone substitutes include calcium phosphate ceramics, collagen-based scaffolds, and allografts. This intervention is performed intraoperatively and aims to improve the biological activity of otherwise mainly osteoconductive materials.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
St. Marien-Hospital Mülheim an der Ruhr
Mülheim, 45468, Germany
100 participants (actual enrollment reported by the registry).
First Submitted
April 17, 2026
First Posted
May 1, 2026
Study Start
July 1, 2024
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
March 1, 2026
Actual (reported)Study Completion
March 1, 2026
Actual (reported)Last Updated
May 1, 2026
Record last verified: 2026-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: